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ABSTRACT
Blood samples were collected for quantitative 16S rDNA analysis from the vascular access device (VAD)
of patients presenting with fever at participating centres of the UK Children’s Cancer and Leukaemia
Group. In total, 260 of 301 episodes of fever were evaluable and were classiﬁed as probable, possible,
unlikely or unclassiﬁable VAD-associated infection. The sensitivity of the 16S rDNA assay declined
concomitantly with delays from time of presentation to sampling. The sensitivity with >0.125 pg of
bacterial DNA ⁄lL of whole blood was 80% for the 20 probable VAD-associated infections diagnosed
with samples collected on the day of or day following presentation. The speciﬁcity rose with increasing
amounts of bacterial DNA, from 93% with >0.125 pg, to 98% with 0.25–0.5 pg, and to 100% with
>0.5 pg ⁄ lL blood. The positive predictive value (for probable or possible) was 88% (95% CI 70–98%)
with 0.25 pg ⁄ lL, and 100% (95% CI 83–100%) with >0.5 pg ⁄lL. All 18 (6.8%) episodes with >0.5 pg of
bacterial DNA ⁄lL blood were associated with positive blood cultures. Identiﬁcations derived from the
DNA sequence were consistent with the blood culture identiﬁcations for 15 of the 17 episodes with a
DNA sequence identiﬁcation. The VAD was removed because of suspected infection in six (2.8%) of 216
episodes with <0.125 pg of bacterial DNA ⁄lL, in one (5%) of 20 episodes with 0.125–0.25 pg ⁄ lL, in one
(16.7%) of six episodes with 0.25–0.5 pg ⁄lL, and in nine (50%) of 18 episodes with >0.5 pg ⁄lL. A
bacterial DNA concentration of >0.5 pg ⁄lL in blood drawn through a central venous catheter at the time
of fever presentation had a high positive predictive value for VAD-associated infection and predicted an
increased risk of VAD removal because of suspected infection.
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INTRODUCTION
Vascular access devices (VADs) include transcu-
taneous catheters and implantable ports. These
devices have become essential for the manage-
ment of certain groups of patients, e.g., those
requiring intravenous nutrition, treatment for
cancer or intensive care. However, infectious
complications arise in 5–26% of patients with a
VAD [1], with >50% of hospital-acquired blood-
stream infections in the UK being device-related,
most frequently involving a central venous cath-
eter [2–4].
Children undergoing treatment for cancer usu-
ally require the use of a VAD, e.g., an implanted
port, for infusion of anti-cancer drugs, complex
drug and hydration schedules, blood product
support and, frequently, for parenteral nutrition.
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The rate of VAD-associated infection in children
undergoing treatment for cancer varies from 1.7
to >5.0 ⁄ 1000 VAD days [3,5–7]. Biomedical device
infections can be diagnosed when a patient with
few other risk-factors for infection develops signs
and symptoms of infection associated with
inﬂammation at the site of the device, or fever
or rigor following VAD manipulations, or follow-
ing isolation of commensal skin bacteria from
multiple blood cultures. The diagnosis is most
difﬁcult in immunocompromised patients, for
whom the clinical presentation may be non-
speciﬁc. Even a tunnel infection may be difﬁcult
to diagnose, becoming apparent only when the
neutrophil count recovers.
Traditional methods used for the diagnosis of
VAD-associated infection have relied on clinical
features combined with quantitative microbiology
[8–10]. The highest levels of sensitivity and
speciﬁcity for quantitative microbiological
methods are achieved when blood is collected
from both the VAD and a peripheral blood vessel,
so that the numbers of bacteria ⁄unit volume of
blood can be compared [11]. Reliance on paired
blood samples is problematical in children with
cancer, because of resistance (by staff, patients
and parents) to the routine collection of peri-
pheral blood samples. Children undergoing treat-
ment for cancer receive frequent and extended
courses of antibiotics, both for prophylaxis and
for treatment of infection; thus, an additional
problem is that concurrent antibiotic therapy
reduces the reliability of diagnostic methods
based on laboratory culture.
Improved methods for diagnosis of VAD-asso-
ciated infection have the potential to reduce
unnecessary removal of VADs and to facilitate
prompt implementation of targeted treatment.
This study describes an evaluation of a novel
molecular method that uses quantitative 16S
rDNA detection for the diagnosis of VAD-associ-
ated infection [12]. The evaluation was carried out
in children receiving treatment for cancer.
PATIENTS AND METHODS
The study was coordinated through the Supportive Care
Group of the Children’s Cancer and Leukaemia Group
(CCLG), and involved a number of UK centres. The protocol
for the study was agreed by the CCLG and received ethical
approval through the Trent Multi-centre Research Ethics
Committee (ref. no. 05 ⁄MRE04 ⁄ 23). Each participating centre
received local site-speciﬁc ethical and research approval. The
centres that participated in the study were Belfast, Bristol,
Great Ormond Street (London), Liverpool, Newcastle, Not-
tingham, Royal Marsden and University College Hospital
(London).
Children, adolescents or young adults, aged 0–18 years,
who were undergoing treatment for cancer ⁄ leukaemia, or who
were immunosuppressed with a severe haematological dis-
order, were eligible for the study if the routine standard of care
required a tunnelled single-, double- or triple-lumen VAD or
implanted vascular port, and if the VAD or port would be
required for a minimum of 3 months. Patients who had an
indwelling VAD in situ were eligible if they had not received
intravenous antimicrobial therapy during the preceding
2 weeks. Written informed consent was required from the
parent ⁄ guardian, or from the patient where appropriate.
Patients who failed to meet these criteria, and those with
untunnelled or short-term VADs, were excluded. Eligible
patients were invited to participate soon after insertion of a
VAD, or at a later outpatient visit or inpatient stay (in the case
of patients with existing devices).
When a recruited patient presented with a febrile episode,
sampleswere collected through theVADfor 16S rDNAanalysis.
A febrile episode was deﬁned as a temperature of either
>38C for >4 h, or >38C on two occasions >4 h apart within a
24-h period, or >38.5C on one occasion, or was established
according to the presenting centre’s deﬁnition of fever.
Samples for quantitative 16S rDNA analysis
Venous blood was collected in 2-mL vacutainer tubes (Vacu-
ette K3E; Becton Dickinson, Oxford, UK) from each lumen of
the VAD when patients presented with fever. It is routine
practice in many CCLG centres to withdraw and discard a
small volume of blood before collecting blood for culture or
other analyses. This ‘discard’ blood was accepted as a suitable
sample for 16S rDNA analyses. Samples were stored at
participating centres at less than or equal to –20C until
collected in batches for transport on dry ice to the laboratory at
Barts and the London NHS Trust (London, UK). Routine
samples were also collected at the time of presentation,
including blood for culture. Centres were encouraged to send
VAD tips for quantitative culture, particularly if a VAD was
removed for suspected VAD-associated infection.
Samples were analysed for bacterial 16S rDNA when they
had been collected within 24 h before or 72 h after the start of
antibiotic treatment. The date of sampling was recorded so that
delays in sampling could be taken into account in the analysis.
Clinical data collection
Clinical data were collected at baseline (within 72 h of fever
presentation), and at 4 weeks after presentation, using stan-
dard questionnaires. The baseline data sheet at 72 h requested
information concerning diagnoses, samples collected for
laboratory analyses, VAD details (e.g., number of lumens),
antibiotics administered, and symptoms and signs at presen-
tation (including chills, fever, rigors or hypotension associated
with VAD manipulations).
The data sheet completed at 4 weeks requested the results
of laboratory investigations, details of antibiotics prescribed,
duration of fever, clinical response to treatment, details of
VAD management (including whether the VAD was removed
as part of the management of suspected VAD-associated
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infection), other sources of infection, speciﬁc agents of infec-
tion identiﬁed, and the impression of and classiﬁcation of the
episode by the clinician responsible for the patient’s care.
Clinical data sheets were returned to the CCLG data centre
in Leicester, where the data were extracted and placed in an
Excel database. The molecular test results and clinical data-
bases were merged for the analysis of test performance.
Deﬁnitions of VAD-associated infection
Febrile episodes were classiﬁed as probable, possible, unlikely
or unclassiﬁable bacterial VAD-associated infections. The
classiﬁcation of the fever episodes was carried out at the
CCLG data centre by staff who were unaware of the results of
the 16S rDNA analyses. The deﬁnitions were agreed by clinical
collaborators in CCLG centres, and broadly reﬂected the
criteria used in the CCLG centres for deﬁning VAD-associated
infection.
Episodes were classiﬁed as probable if any of the following
criteria were met: (i) two or more blood cultures collected
within 72 h of presentation that were culture-positive for a
skin commensal, e.g., a coagulase-negative staphylococcus
(including positive blood cultures from different lumens of
the same VAD on the same or different occasions of
sampling); (ii) a positive blood culture from a patient with
signs or symptoms of infection, and an isolate with the same
identiﬁcation and antibiotic susceptibility proﬁle as that of an
isolate from the VAD tip culture; (iii) fever, chills and ⁄ or
hypotension associated with VAD manipulations, together
with a response to treatment appropriate for central venous
catheter (CVC)-associated infection (intravenous antibiotic
treatment, and ⁄ or VAD removal); response to treatment was
deﬁned as resolution of fever within 5 days of the initiation of
treatment, with no recurrence within 5 days of discontinuing
antibiotic treatment, and antibiotic treatment for VAD-associ-
ated infection required that all of the lumens were exposed to
antibiotic treatment; or (iv) inﬂammation extending at least
2 cm along the tunnel from the VAD exit site in a patient with
systemic signs or symptoms of infection.
Episodes were deﬁned as possible when there was a VAD
in place and the patient’s clinical condition resolved in
response to appropriate (for episodes with positive micro-
biological identiﬁcation, e.g., a blood culture isolate) and
speciﬁc treatment for bacterial VAD-associated infection.
Speciﬁc treatment for VAD-associated infection required that
all of the lumens were exposed to antibiotic treatment, and ⁄ or
the VAD was removed. A complete response to treatment was
deﬁned as resolution of fever within 5 days of the initiation of
treatment, and no recurrence of fever within 5 days of
discontinuing antibiotic therapy.
Episodes of unlikely bacterial CVC-associated infection
were those in which the patient showed a complete
resolution of symptoms without speciﬁc treatment for
bacterial CVC-associated infection. These episodes may or
may not have been associated with positive blood cultures.
Episodes in which the VAD was removed for suspected
fungal CVC-associated infection were classiﬁed as unlikely
(bacterial) CVC-associated infection.
Unclassiﬁable episodes were deﬁned as those that did not
ﬁt the deﬁnition of probable, possible or unlikely bacterial
VAD-associated infection. These included episodes for which
there was insufﬁcient information to classify an episode,
episodes in which a patient remained febrile with or without
speciﬁc treatment of VAD-associated infection for >2 weeks,
and episodes in which there was recurrence of fever within
5 days of discontinuing systemic antibiotic therapy.
Episodes that were unclassiﬁable using the above deﬁni-
tions were reclassiﬁed using the classiﬁcations probable,
possible, unlikely and unclassiﬁable, as recorded by the
clinician responsible for patient care at 4 weeks after episode
presentation. Only those episodes unclassiﬁable according to
the predeﬁned criteria and clinician judgement were consid-
ered to be unclassiﬁable in the ﬁnal analyses. Clinicians had
access to the deﬁnitions used in the formal classiﬁcation.
Molecular methods
The development of these methods has been described
previously by Warwick et al. [12]. For the purposes of this
study, all extractions were performed as described below,
although subsequent work is now performed using automated
DNA extraction methods.
DNA extraction from clinical and control samples. DNA was
extracted from 200-lL aliquots of EDTA-anticoagulated whole
blood. Each sample was mixed with 1200 lL of freshly
prepared 0.17 M ammonium chloride and incubated at room
temperature for 30 min. Following centrifugation at 11 600 g
for 10 min, the pellet was washed twice with 500 lL of sterile
saline (0.9% w ⁄v) and then extracted using a QIAmp DNA
minikit (Qiagen, Hilden, Germany). The pellet was resus-
pended in 180 lL of Qiagen ATL buffer (containing EDTA and
SDS) and exposed to six freeze–thaw cycles (cycling between
)70C and 50C), with vortexing between cycles, before being
heated in a boiling water bath for 10 min. The remainder of the
extraction procedure was performed according to the manu-
facturer’s protocol. DNA was eluted in 50 lL of buffer and
stored at –20C until analysis.
Several controls were run routinely with each batch of tests.
These included blood samples from a healthy individual with
and without spiking with bacteria. An extraction control of
blood spiked with 103 CFU of Staphylococcus epidermidis ⁄ lL
was found to yield DNA levels close to the lower limit of
detection. Bacterial DNA controls containing known amounts
of bacterial DNA extracted from Enterococcus faecalis (100 pg to
100 fg) and a negative control (with template DNA omitted to
detect reagent contamination) were also included in each run.
PCR conditions (TaqMan assay). Real-time PCRswere performed
using the ABI Prism 7900HT sequence detection system
(Applied Biosystems, Warrington, UK) in optical 384-well
plates. Reaction mixtures contained (1· dilution) TaqMan
universal PCR mastermix (Applied Biosystems), 300 nM each
of the forward and reverse primers, 100 nM ﬂuorescent probe,
2 lL of template DNA, and water to a ﬁnal volume of 20 lL.
The cycling conditions comprised 50C for 2 min and 95C for
10 min, followed by 40 cycles of 95C for 125 s and 60C for
1 min. The primer sequences were: forward primer 5¢-TCCT
ACGGGAGGCAGCAGT; reverse primer 5¢-GGACTACCA
GGGTATCTAATCCTGTT; and probe sequence, 5¢-CGTATTA
CCGCGGCTGCTGGCAC [12].
The threshold cycle (ct) value, which is inversely propor-
tional to the log of the amount of target DNA initially present,
was calculated using SDS software v.2.0 (Applied Biosystems).
All samples were run in triplicate. The median cycle result was
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used to calculate bacterial DNA concentrations by comparison
with a DNA standard curve constructed from the results
obtained using DNA standards.
Identiﬁcation using DNA sequencing. When a sample contained
>0.5 pg of bacterial DNA ⁄lL of blood, it was possible to
amplify a c. 1300-bp 16S rRNA gene fragment directly from the
DNA extracts using oligonucleotide primers 5¢-TCAGATT-
GAACGCTGGCGGC (forward) and 5¢-CCCGGGAACGTATT-
CACCG (reverse). Each PCR was performed in a total volume
of 25 lL containing 0.2 lM each primer, 2 mM MgCl2, 1 U Taq
DNA polymerase (Promega, Southampton, UK), 1· PCR buffer
(Promega) and 2 lL DNA extract. PCRs comprised 95C for
3 min, followed by 30 cycles of 95C for 10 s, 58C for 20 s and
72C for 30 s using a Palm Cycler (Corbett Research, Sydney,
Australia). PCR products were sequenced, using the forward
primer and the internal primer 5¢-TGCCAGCAGCCGCGGTA-
ATA, on an ABI Prism 3700 DNA Analyzer (PE Biosystems,
Warrington, UK). The sequences were aligned using the
Clustal W algorithm to produce a consensus sequence. This
was analysed using the BLAST algorithm at the NCBI site [13].
Results for samples containing 0.125–0.5 pg of bacterial
DNA ⁄lL of extracted whole blood were only reported as
positive when the concentration was >0.125 pg ⁄ lL on repeat
testing. All of the results of the molecular tests were entered
into an Excel spreadsheet for statistical analysis.
Statistical methods
Sensitivity, speciﬁcity and positive and negative predictive
values were calculated, together with exact binomial 95% CIs.
Stata v.9 software (Stata Corp., College Station, TX, USA) was
used for the analyses. When multiple lumens were present, the
highest bacterial DNA concentration was used in the episode
analysis.
RESULTS
Samples and clinical data sheets were collected
from 301 episodes of fever in 207 children. The
numbers recruited by each centre were: Belfast 15,
Bristol 51, Great Ormond Street 2, Liverpool 63,
Newcastle 63, Nottingham 19, Royal Marsden 19,
and University College Hospital 31. Forty-one
episodes were excluded from analysis. The rea-
sons for exclusion were: incomplete clinical data
collection, problems with consent, inappropriate
sample storage or loss of samples, or antibiotics
given intravenously during the 14- to 3-day
period before the onset of fever (ten episodes);
failure to collect samples from all lumens (26
episodes); and development of signs and ⁄ or
symptoms of VAD-associated infection >48 h
after fever presentation (ﬁve episodes). The pro-
portion of episodes excluded from analysis
ranged from 0% to 33.3% for each centre. There
was no signiﬁcant difference among centres in
the proportion of episodes excluded. The ﬁve
episodes of late presentation of VAD-associated
infection were diagnosed 5–23 days after initial
presentation. Four of these ﬁve episodes were
associated with positive blood cultures, and one
episode was a tunnel infection. In one of these
episodes, a sample was collected for 16S rDNA
analysis at the time of fever recurrence (5 days
after initial presentation), and this sample gave a
bacterial DNA concentration of 0.34 pg ⁄ lL blood,
while blood cultures taken at the same time grew
Stenotrophomonas maltophilia.
Overall, VAD tips were sent for culture from 16
(84%) of 19 episodes in which the VAD was
removed, and from 14 (82%) of 17 episodes in
which the VAD was removed for suspected VAD-
associated infection.
The patient had received oral antimicrobial
agents in the previous 2 weeks in 133 (51.1%) of
the 260 evaluable fever episodes, with 125 (48.1%)
receiving an antibacterial agent. In 117 episodes,
these antibacterial agents were prophylactic
(trimethoprim–sulphamethoxazole in 110 epi-
sodes, and ciproﬂoxacin in seven episodes). In
17 episodes, oral antibacterial agents were being
administered for treatment at the time of fever
presentation (with or without prophylactic
agents). Nine patients were receiving both pro-
phylactic and therapeutic antibacterial agents.
The date on which the blood for 16S rDNA was
collected was the date of fever presentation
(day 0) in 189, day 1 in 46, day 2 in 21 and
day 3 in four of the 260 episodes. In those
episodes where the date of collection was on
day 0 or 1 of fever, 67 patients had been started on
intravenous antibiotics before the DNA sample
was collected. The classiﬁcation of fever episodes
is shown in Table 1.
The bacterial DNA detection method had a
relatively high detection level of c. ten genome
copies (0.1 pg) ⁄ lL of blood. In some cases, the
bacterial DNA concentration exceeded 100 pg ⁄ lL,
which is equivalent to 107 genomes ⁄mL. Blood
samples were aspirated directly from the VAD
without ﬂushing theVAD, so these very high levels
may be a consequence of undiluted accumulated
biomass from the VAD. However, the results were
reproducible with repeated testing and were
calculated against a standard curve constructed
using known DNA standards.
Sensitivity and speciﬁcity for detecting line
infection with various concentrations of bac-
terial DNA in blood are shown in Table 2. The
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sensitivity improved substantially when the
blood samples for bacterial culture and bacterial
DNA analysis were collected temporally close
together, and even more so if they were collected
before intravenous antibiotics had been given.
The speciﬁcity was high for a cut-off point at
0.25 pg of bacterial DNA ⁄ lL, and reached 100%
with 0.5 pg of bacterial DNA ⁄ lL.
The centre protocols for management of febrile
episodes speciﬁed treatment for VAD-associated
infection for patients who had unresolved pyrexia
after 48–96 h of empirical antibiotic treatment;
thus, many of the episodes of possible VAD-
associated infection were effectively protocol-
deﬁned, and included a signiﬁcant proportion of
episodes associated with mucositis, viral infection
or other potential causes of fever. When samples
were collected on day 0 or day 1, the sensitivity of
a bacterial DNA concentration of 0.125 pg ⁄ lL for
possible VAD-associated infection was 33.3%
(13 ⁄ 39). The four probable episodes that yielded
negative bacterial DNA results when samples
were collected on day 0 or day 1 were all deﬁned
as probable, based on the presence of fever, chills
and ⁄ or hypotension associated with VAD manip-
ulations and a response to treatment appropriate
for CVC-associated infection. The positive predic-
tive value of a probable or possible episode vs.
unlikely or unclassiﬁable infection was 88%
(21 ⁄ 24) (95% CI 68–97%) at >0.25 pg, and 100%
(18 ⁄ 18) (95% CI 81–100%) at >0.5 pg.
Each of the 18 episodes with a bacterial DNA
concentration of >0.5 pg ⁄lL was associated with
a positive blood culture. Three of the six episodes
with 0.25–0.5 pg ⁄ lL were associated with positive
blood cultures, as were nine of 20 episodes with
0.125–0.25 pg ⁄ lL. There were 22 episodes with
positive blood cultures and bacterial DNA con-
centrations of <0.125 pg ⁄lL. Of these, nine were
positive with a skin bacterium in only one of
multiple blood cultures (suggesting blood culture
contamination), and seven had blood collected for
DNA testing at least 1 day after the start of
intravenous antibiotics and blood culture; the
sample for one case was collected 2 days after
blood culture.
Sequencing of the bacterial DNA in samples
with >0.5 pg ⁄ lL was performed following ampli-
ﬁcation of 16S rDNA from DNA extracts. The
sequence identiﬁcations obtained are summarised
in Table 3.
In 17 (6.5%) of the 260 evaluable episodes,
VADs were removed for suspected VAD-associ-
ated infection. Only two episodes in which the
VAD was removed (and where the bacterial DNA
samples were collected on the date of presenta-
tion or the day after, and intravenous antibiotics
had not been given on the previous days) yielded
a bacterial DNA concentration of <0.125 pg ⁄ lL.
One of these two episodes was associated with
diarrhoea and Clostridium difﬁcile toxin-positive
stool tests, and the other was associated with
isolation of parainﬂuenza virus 3 from a naso-
pharyngeal sample.
The proportion of VADs removed within
4 weeks of fever presentation because of suspected
infection increased as the bacterial DNA concen-
tration increased. The VAD was removed because
of suspected infection in six (2.8%) of 216 episodes
with <0.125 pg ⁄ lL, one (5%) of 20 episodes with
0.125–0.25 pg ⁄ lL, one (16.7%) of six episodes
with 0.25–0.5 pg ⁄ lL, andnine (50%) of 18 episodes
Table 1. Classiﬁcation of episodes of fever among chil-
dren with vascular access device (VAD)-associated infec-
tion
VAD infection
A B C
Eligible,
all lumens
sampled and
excluding hospital-
acquired VAD
infection (%)
Category A,
plus collected
on ﬁrst or
second
day of fever
(%)
Category B,
plus intravenous
antibiotics not
given on days
before DNA
sample (%)
Probable 26 (10) 20 (8.6) 15 (7.8)
Possible 43 (16.5) 39 (16.7) 29 (15.0)
Unlikely 190 (73) 174 (74.4) 148 (76.7)
Unclassiﬁable 1 (0.4) 1 (0.4) 1 (0.05)
Total 260 (100) 234 (100) 193 (100)
Table 2. Sensitivity and speciﬁcity for detection of line
infection with different bacterial DNA concentrations in
blood
Cut-off point
(pg ⁄ lL)
A B C
Eligible,
all lumens
sampled and
no subsequent
hospital-acquired
line infection
Category A,
plus collected
on ﬁrst or
second day
of fever
Category B,
plus intravenous
antibiotics not
given on days
before DNA
sample
Sensitivity (probable line infection) (%)
0.125 65 (44–83) 80 (56–94) 87 (60–98)
0.25 46 (27–67) 60 (36–81) 73 (45–92)
0.5 42 (23–63) 55 (31–77) 67 (38–88)
n 26 20 15
Speciﬁcity (unlikely line infection) (%)
0.125 93 (89–96) 93 (8–96) 94 (89–97)
0.25 98 (95–100) 98 (95–100) 98 (94–100)
0.5 100 (98–100) 100 (98–100) 100 (97.5–100)
n 190 174 148
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with >0.5 pg ⁄lL. The survival (retention) curve for
VADs is shown in Fig. 1. In comparison, the VAD
was removed because of suspected infection in 15
(28.8%) of 52 episodes associated with positive
blood cultures.
There was no relationship between C-reactive
protein (CRP) levels, measured at the time of
presentation, and bacterial DNA concentrations in
the 149 episodes in which the CRP level was
measured. Episodes classiﬁed as probable or
possible VAD-associated infection had a higher
rate of CRP positivity (>10 mg ⁄L) than those
classiﬁed as unlikely VAD-associated infection
(97.5 vs. 82.7%; p 0.016). There was no correlation
between the duration of use of intravenous
antibiotics and bacterial DNA concentrations,
but cases with negative bacterial DNA assays
had a more variable duration of intravenous
antibiotic usage than those with positive bacterial
DNA assays (SD 8.3 with bacterial DNA
<0.125 pg ⁄ lL; SD 5.4 with bacterial DNA
>0.125 pg ⁄ lL).
DISCUSSION
There is a need for improved diagnostic methods
for the diagnosis of VAD-associated infection in
children with cancer, particularly because of the
reluctance to collect peripheral blood samples
routinely. The method reported here has a rela-
tively high detection level of c. ten genome
copies ⁄ lL of blood. This relatively high detection
level probably explains the episodes with positive
blood culture and negative bacterial DNA test
results, although the possibility of blood culture
contamination cannot be excluded. Nevertheless,
the method yielded sensitivity (for episodes
deﬁned as probable VAD-associated infection),
speciﬁcity and positive predictive values similar
to those reported for paired quantitative blood
cultures [11]. Unlike many reported evaluations,
this study was performed by laboratory staff
working at a distant site who were unaware of the
clinical details of individual patients, and the
results were achieved despite the frequent expo-
sure of patients to oral antibiotics in the 2-week
period preceding fever presentation.
The method described in this study has a
number of advantages over paired quantitative
blood cultures, including a requirement for vas-
cular access samples only, the use of small
volumes of discard blood, and the potential for
automation. The manual DNA extraction method
described in this study is time-consuming, but
subsequent evaluations have obtained compara-
ble results using automated DNA extraction
systems, with considerable savings in technician
time (results not shown). The quantitative bacte-
rial DNA method used in the present study does
not generate a product that is sufﬁciently infor-
mative to allow bacterial identiﬁcation. When the
bacterial DNA concentration was >0.5 pg ⁄lL, it
was possible to identify bacteria by ampliﬁcation
of a discriminatory 16S rDNA region, followed by
sequencing of the ampliﬁed product. The majority
of identiﬁcations according to molecular and
conventional laboratory methods were consistent.
Discrepant identiﬁcations probably reﬂect the
limitations of routine laboratory standard operat-
ing procedures.
Table 3. Identiﬁcation of bacteria contained in blood
samples following DNA sequencing of 16S rDNA ampli-
ﬁed from samples containing >0.5 pg of bacterial DNA ⁄ lL
Bacterial DNA
(pg ⁄ lL blood) Sequence identiﬁcation Blood culture identiﬁcation
0.7 Staphylococcus spp. Coagulase-negative staphylococcus
0.7 Staphylococcus epidermidis Coagulase-negative staphylococcus
1.1 Acinetobacter spp. Acinetobacter spp.
1.1 Staphylococcus aureus S. aureus
1.4 Enterobacter spp. Enterobacter cloacae
1.6 S. epidermidis Coagulase-negative staphylococcus
1.6 Klebsiella oxytoca K. oxytoca
2.9 Acinetobacter baumannii Acinetobacter spp. ⁄
Pseudomonas aeruginosa
5.6 S. aureus S. aureus
9.7 S. epidermidis Coagulase-negative staphylococcus
11.25 Vibrio harveyi V. harveyi
12.8 A. baumannii A. baumannii
13.1 Bacillus cereus Bacillus spp.
13.1 K. oxytoca K. oxytoca
21.3 Escherichia coli Enterobacter spp.
21.6 Corynebacterium
tuberculostearicum
Coagulase-negative staphylococcus
160 Unreadable sequence Mixed Staphylococcus spp.
425 P. aeruginosa P. aeruginosa
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Fig. 1. Survival (retention) curves for vascular access
devices in the 4-week period following presentation with
various bacterial DNA concentrations in blood.
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Current practice in paediatric oncology in the
UK and much of Europe [14] is to retain VADs if
removal can be avoided; thus, in the present
study, VAD removal occurred >7 days after fever
presentation in 50% of cases, precluding the use
of catheter segment culture as a reference method
[15]. Collection of peripheral samples for blood
culture is not routine practice in paediatric
oncology, despite being recommended in policy
documents [16], so the use of paired quantitative
blood cultures was precluded as a reference
standard. Instead, clinical and laboratory criteria
was used to deﬁne VAD infection categories. This
approach has the disadvantage of deﬁning some
episodes as probable VAD-associated infection
based on clinical criteria alone, without any
requirement for corroborating laboratory evi-
dence. Episodes deﬁned as probable VAD-asso-
ciated infection, but with negative bacterial DNA
test results, were all placed in the category
deﬁned by ‘fever, chills and ⁄ or hypotension
associated with VAD manipulations’.
Novel methods for the diagnosis of VAD-
associated infections have been reported previ-
ously, but these share many of the problems of
traditional approaches, or have other disadvan-
tages, and have therefore not been universally
adopted. Methods relying on microbial culture,
e.g., differential time-to-positivity [17], are unre-
liable in patients treated with antibiotics. This
method also requires the collection of a sample
from a peripheral vessel, which may be unaccept-
able with some patients, especially children.
Methods that require invasive sampling of the
lumen of the VAD [18] cannot be used in narrow
bore VADs, e.g., those used in infants, and there is
the potential for complications arising from dis-
turbance of thrombi attached to the lumen or tip
of the VAD. This methodology is time-consuming
and requires specialist equipment. Newer radio-
logical approaches, e.g., positron emission tomo-
graphy [19], the use of labelled antimicrobial
peptides [20], and the detection of speciﬁc
immune responses, may also have a role in the
diagnosis of device-associated infections [21], but
none of these methods has been evaluated for the
diagnosis of VAD-associated infection. These
techniques are also likely to be expensive and
available only in specialist centres.
Previous reports have suggested a link between
time-to-positivity (a marker of bacterial load) and
outcome for both Staphylococcus aureus [22] and
Streptococcus pneumoniae [23] bloodstream infec-
tions. In the present study, increasing bacterial
DNA load in blood samples drawn through the
VAD was associated with an increasing risk of
VAD removal for suspected infection. Informa-
tion was only collected for 4 weeks after fever
presentation. Prolonging the period of data
collection might allow a better assessment of
the implications for outcomes in patients with
high bacterial load VAD-associated infection.
Bacterial load is an important determinant of the
efﬁciency of sterilisation and disinfection pro-
cesses, so it is perhaps not surprising to ﬁnd a
relationship between the effectiveness of antimi-
crobial treatment of VAD-associated infection and
bacterial load. The increased variability in dura-
tion of intravenous antibiotic treatment in patients
with and without detectable levels of bacterial
DNA is consistent with the hypothesis that
detection of bacterial DNA identiﬁed a discrete
group of episodes within an aetiological category
(VAD-associated infection).
If conﬁrmed in other studies, these results
have implications for the management of
patients with VAD-associated infection, and also
for studies of interventions designed to prevent
or treat VAD-associated infection. The bacterial
DNA test can give results within a few hours
of sample collection, and therefore has the
potential to allow early speciﬁc interventions
targeted at optimising the outcome for patients
with VAD-associated infection. Further work
should examine the persistence of bacterial
DNA, particularly as a marker of response to
treatment.
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